* Minimal intervention. Bandaging and antibiotics usually not required.
* Complete response was defined as complete removal of the tumor.Eisenhauer EA, et al. European Journal of Cancer 2009;45(2):228–47.
** Results from pivotal field efficacy study: 68/78 dogs achieved a complete response at 28 days after one or two treatments of STELFONTA®.
* At the site of STELFONTA treatment.
Study design: A multi-center, randomized, controlled, investigator- and owner-masked clinical study in 123 client-owned dogs with MCT measuring ≤10cm3. Effectiveness was evaluated using response evaluation criteria in solid tumors (RECIST), where complete response was defined as complete removal of the tumor.Eisenhauer EA, et al. European Journal of Cancer 2009;45(2):228–47. Dogs in the STELFONTA® group were treated once at the start of the study, in addition to receiving concurrent medications. Patients in the STELFONTA® treated or the control group that did not achieve a complete response at Day 28 were eligible to receive a second treatment or a first treatment if the patient was in the original control group. All patients in both the STELFONTA® treated and the control group received concurrent medications. Patients that achieved a complete response at Day 28 in either phase were followed for 12 weeks after the final treatment. Where possible, patients were assessed at 12 months for tumor recurrence.
FDA-approved local treatment for non-metastatic Mast Cell Tumors
Indicated for the treatment of:
STELFONTA® (tigilanol tiglate injection) is an intratumoral injection indicated for use in dogs for the local treatment of MCTs that are:
Acute inflammatory response with swelling and erythema noted on the tumor margins and surrounding tissues.Melo SR, et al. Veterinary Cancer Society, Houston, Texas, USA.
Necrotic destruction is seen – in dogs this means blackening, shrinkage and leakage of thick discharge
57% wounds fully healed
78% wounds fully healed
96% wounds fully healed
“… By following the treatment process to the letter, Daisy coped exceptionally well, and it’s now 18 months later with no recurrence, and her quality of life is excellent. Daisy is now 10 and enjoying her later years with typical Jack Russell zest, energy and appetite!”
Brigitte and Brian Wright
Owners of Daisy
STELFONTA® was discovered by Australian company QBiotics, who found a new biologically active chemical (tigilanol tiglate) in the seed of the Australian native blushwood plant (Fontainea picrosperma).
Common adverse events seen following STELFONTA® treatment
For information on contraindications and warnings,
please refer to the Product Insert
WARNING: SEVERE WOUND FORMATION IN HUMANS; EXTENSIVE WOUND FORMATION, MAST CELL DEGRANULATION, AND DEATH IN DOGS DUE TO MAST CELL DEGRANULATION
Accidental self-injection of STELFONTA® may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or view the Product Insert.
FOR PET OWNERS
Wear disposable gloves when cleaning the treated tumor site to avoid contact with any residual drug. Thoroughly wash your skin that comes in contact with the treated tumor site, wound, or wound discharge. Ensure your dog receives their prescribed medications to decrease the potential for severe, life-threatening adverse reactions. Monitor your dog during the healing process and contact your veterinarian if you notice excessive pain, lameness, tiredness, refusal to eat for more than one day, repeated vomiting or diarrhea, trouble breathing, changes to the treated tumor site (including increased or excessive swelling and bruising, extensive wound formation, increased irritation) or any other symptoms that concern you. For full prescribing information, contact Virbac at 1-800-338-3659 or view the Product Insert.